ES--How will this weigh on Jmar's product?>>TRANSMEDICA to Receive Vital New Patent for Laser Lancet
LITTLE ROCK, Ark.--(BW HealthWire)--Aug. 18, 1998--TRANSMEDICA International, Inc. announced today that it has received a letter of allowance from the United States Patent Office that will secure its intellectual property position for the use of lasers in drawing capillary blood, and for the transdermal administration of pharmaceuticals.
The new patent will protect the methods of use of the company's Laser Lancet(R). The Laser Lancet(R) has already received device patent protection.
''The patent office's letter of allowance secures our position as the only company with broad patented technology for capillary blood draws and laser-assisted transdermal drug delivery,'' said Charles Vestal, TRANSMEDICA's President, and Chief Executive Officer. ''Our ability to provide this technology is a significant benefit to both patients and health care workers,'' Vestal added.
The TRANSMEDICA Laser Lancet(R) is the only patented laser device cleared by the U.S. Food and Drug Administration for all capillary blood draws for screening purposes. The Laser Lancet(R) eliminates the need for sharps to effect capillary blood draws, thereby making the procedure safer for patients and health care workers.
TRANSMEDICA has many additional patent applications pending. ''Our research and development have demonstrated exciting and important new applications for our technology,'' said Vestal. ''We will be filing new patent applications, and we will continue to protect those already issued,'' he added.
The Laser Lancet(R) is manufactured for TRANSMEDICA by LaBarge, Inc. (AMEX:LB - news), a St. Louis, MO firm that designs and manufactures high performance electronics for a variety of industries. |
